IP Verse

Lindis Biotech competitive analysis

Loading summary...

Latest oppositions filed by Lindis Biotech

Explore patent oppositions filed by Lindis Biotech against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 23, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP2637670	Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains	AMGEN	Dec 7, 2017

Latest patents of Lindis Biotech opposed by its competitors

Explore Lindis Biotech's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025

Patent Number	Grant Date	Title	Total Oppositions
EP3177645	Feb 17, 2021	Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of Cancer	10

Latest publications and patents of Lindis Biotech New

Explore the latest publications and patents granted to Lindis Biotech, showcasing their recent innovations and technological advancements.

Last updated on: Oct 17, 2025

Publication Number	Publication Date	Title	Legal Status
Get instant update for new patents of Lindis Biotech
EP3177645	Feb 17, 2021	Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of Cancer	Revoked

Latest PTAB cases involving Lindis Biotech

Discover the latest PTAB cases involving Lindis Biotech, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Lindis Biotech with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
LINDIS BIOTECH	1	10	-	-
ABBVIE	10	9	-	1
AMGEN	8	138	8	11
AMGEN RESEARCH MUNICH	-	30	-	-